Joann M. Mican, Adrian M. Di Bisceglie, Tse‐Ling Fong, William D. Travis, David E. Kleiner, Bennie Baker, Dean D. Metcalfe – 1 October 1995 – Mastocytosis is a disease of mast cell hyperplasia that may involve several organ systems, including liver. Between 1988 and 1991, we conducted a retrospective‐prospective study of 41 patients with mastocytosis and found 61% had evidence of liver disease.
Syoji Kuroki, Shuichiro Okamoto, Tokio Naito, Hitoshi Oda, Shoji Nagase, Hironori Sakai, Hajime Nawata, Hiroyuki Yamashita, Kazuo Chijiiwa, Masao Tanaka – 1 October 1995 – To examine bile acid synthesis in chronic liver diseases, serum total 7α‐hydroxycholesterol level was measured by gas‐liquid chromatography‐mass spectrometry in patients with cirrhosis (n = 23), patients with chronic hepatitis (n = 21), and control subjects (n = 18). The serum 7α‐hydroxycholesterol levels were significantly lower in patients with cirrhosis than the controls (78 ± 59 pmol/mL vs.
Wan Ping Geng, Andreas J. Schwab, Carl A. Goresky, K. Sandy Pang – 1 October 1995 – The hepatic removal of the glutathione conjugate of bromosulfophthalein (BSPGSH) was studied in the single‐pass perfused rat liver with the multiple indicator dilution (MID) technique against various background concentrations of BSPGSH (20 to 214 μmol/L) over which nonlinear binding to both plasma (albumin) and tissue proteins with two classes of binding sites was found.
Koert P. de Jong, Harold E. Lont, Amelie M. Bijma, Mark A. M. Brouwers, Elisabeth G. E. de Vries, Marco L. van Veen, Richard L. Marquet, Maarten J. H. Slooff, Onno T. Terpstra – 1 October 1995 – Residual tumor in the remnant liver after partial hepatectomy (PH) for colorectal liver metastases is a serious clinical problem. This fact is reflected by the high number of recurrences after potentially curative liver resections. Liver regeneration, it appears, might influence the growth of remaining micrometastases in the liver.
James F. Whiting, Richard M. Green, Adam B. Rosenbluth, John L. Gollan – 1 October 1995 – Tumor necrosis factor–alpha (TNF,α), a cytokine that is produced in a variety of inflammatory diseases associated with cholestasis, is believed to be the primary mediator of the systemic effects of endotoxin. Thus, we have investigated the role of TNFα in the pathogenesis of endotoxin‐induced cholestasis in intact animals, and in the uptake of taurocholate by cultured hepatocytes.
1 October 1995
George Marinos, Francesco Torre, Shilpa Chokshi, Munther Hussain, Berwin E. Clarke, David J. Rowlands, Adrian L. W. F. Eddleston, Nikolai V. Naoumov, Roger Williams – 1 October 1995 – The T helper (Th) cell response to hepatitis B core antigen (HBcAg) was analyzed in 76 chronic hepatitis B virus (HBV) carriers with varying degrees of hepatic inflammation and HBV replication. Fifty‐five patients had active viral replication, 28 with minimal histological changes and normal alanine transaminase (ALT) and 27 with active hepatic inflammation and elevated ALT.
Keith D. Lindor, E. Rolland Dickson, Roberta A. Jorgensen, Monte L. Anderson, Russell H. Wiesner, Gregory J. Gores, Stephen M. Lange, Steven S. Rossi, Alan F. Hofmann, William P. Baldus – 1 October 1995 – Ursodeoxycholic acid (UDCA) and methotrexate (MTX) have both been proposed as treatments for patients with primary biliary cirrhosis (PBC). It has been suggested that a combination of the two drugs may offer advantages over either used separately. In this pilot study, we sought to evaluate the safety and efficacy of this combination for patients with PBC.
Albert D. Min, Henry C. Bodenheimer – 1 October 1995
Katsuya Shiraki, Koujirou Takase, Yukihiko Tameda, Minoru Hamada, Yoshitane Kosaka, Takeshi Nakano – 1 September 1995 – Levels of two types of lectin‐reactive alpha‐fetoprotein (AFP), designated AFP‐L3 and AFP‐P4+P5, were analyzed with Lens culinaris agglutinin A and AFP‐P4+P5 with erythroagglutinating phytohemagglutinin, respectively, in an attempt to determine the utility and significance of these macromolecules as early indicators of hepatocellular carcinoma during the periodic follow‐up of cirrhotic patients.